2024
Toxic Nephropathies of the Tubulointerstitium: Core Curriculum 2024
Krishnan N, Moledina D, Perazella M. Toxic Nephropathies of the Tubulointerstitium: Core Curriculum 2024. American Journal Of Kidney Diseases 2024, 83: 659-676. PMID: 38243994, DOI: 10.1053/j.ajkd.2023.09.017.Peer-Reviewed Original ResearchRenal injurySeverity of renal injuryToxic nephropathyTubulointerstitial renal injuryIrreversible renal injuryToxin-induced renal injuryImmune response genesNephrotoxic riskClinical presentationTubulointerstitial injuryRenal functionClinical manifestationsPatient characteristicsTubular secretionGlomerular filtrationComorbid conditionsMetabolic handlingDrug metabolismExcretory pathwayInjuryTransport defectAdverse effectsTubulointerstitiumNephropathyExogenous toxins
2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2022
Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity
Qian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.Peer-Reviewed Original ResearchUrine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy
Tran AC, Melchinger H, Weinstein J, Shaw M, Kent C, Perazella MA, Wilson FP, Parikh CR, Moledina DG. Urine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy. Practical Laboratory Medicine 2022, 30: e00271. PMID: 35465621, PMCID: PMC9018443, DOI: 10.1016/j.plabm.2022.e00271.Peer-Reviewed Original ResearchTubulointerstitial diseaseKidney biopsyGlomerular diseaseUrine albuminHistological diagnosisUrine uromodulinUrine testsHigher urine albuminUrine sediment microscopyCohort of participantsDipstick hematuriaTubular injuryAppropriate patientsUrine testingMultivariable modelHigher oddsBiopsyClinical decisionSediment microscopyDiseasePatientsHealth biomarkersUrine samplesDiagnosisCohortAcute Interstitial Nephritis and Crystalline Nephropathies
Moledina D, Herlitz L, Perazella M. Acute Interstitial Nephritis and Crystalline Nephropathies. Nephrology Self-Assessment Program 2022, 21: 50-70. DOI: 10.1681/nsap.2022.21.1.5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2021
Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data
Moledina DG, Eadon MT, Calderon F, Yamamoto Y, Shaw M, Perazella MA, Simonov M, Luciano R, Schwantes-An TH, Moeckel G, Kashgarian M, Kuperman M, Obeid W, Cantley LG, Parikh CR, Wilson FP. Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrology Dialysis Transplantation 2021, 37: 2214-2222. PMID: 34865148, PMCID: PMC9755995, DOI: 10.1093/ndt/gfab346.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisInterstitial nephritisUrine biomarkersBiopsy-proven acute interstitial nephritisElectronic health record dataExternal validation cohortTypical clinical featuresBlood urea nitrogenTumor necrosis factorCharacteristic curve analysisHealth record dataExternal validationElectronic health recordsAIN diagnosisModest AUCsSerum creatinineCreatinine ratioKidney biopsyClinical featuresValidation cohortNecrosis factorUnrecognized casesInterleukin-9PatientsUrea nitrogenAKI and Mortality in Patients Prescribed Immune Checkpoint Inhibitor Therapy
Baker M, Yamamoto Y, Perazella M, Parikh C, Wilson F, Moledina D. AKI and Mortality in Patients Prescribed Immune Checkpoint Inhibitor Therapy. Journal Of The American Society Of Nephrology 2021, 32: 132-132. DOI: 10.1681/asn.20213210s1132c.Peer-Reviewed Original ResearchThe Challenges of Acute Interstitial Nephritis: Time to Standardize
Moledina DG, Perazella MA. The Challenges of Acute Interstitial Nephritis: Time to Standardize. Kidney360 2021, 2: 1051-1055. PMID: 35373086, PMCID: PMC8791367, DOI: 10.34067/kid.0001742021.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2020
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete data
2017
Acute Interstitial Nephritis
Moledina D, Perazella M. Acute Interstitial Nephritis. DeckerMed Nephrology Dialysis And Transplantation 2017 DOI: 10.2310/nephro.12028.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements